Vera Therapeutics, Inc.

For the period ended Jun 30, 2026. Filed Aug 10, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 10, 2026

VERA$30.61+2.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Balance Sheets (unaudited)

Condensed Balance Sheets

(in thousands, except share amounts)

	June 30,	December 31,
	2026	2025
Assets
Current assets:
Cash and cash equivalents	$48,876	$354,725
Marketable securities	450,285	359,864
Prepaid expenses and other assets, current	28,332	14,294
Total current assets	527,493	728,883
Other assets, noncurrent	5,491	5,850
Total assets	$532,984	$734,733
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$14,573	$21,898
Accrued expenses and other liabilities, current	33,748	31,557
Total current liabilities	48,321	53,455
Long-term debt	75,228	74,838
Other liabilities, noncurrent	1,677	1,919
Total liabilities	125,226	130,212
Stockholders’ equity
Class A common stock, $0.001 par value; 500,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 71,955,885 and 71,267,429 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	72	71
Additional paid-in capital	1,399,459	1,364,529
Accumulated other comprehensive (loss) income	(403)	786
Accumulated deficit	(991,370)	(760,865)
Total stockholders’ equity	407,758	604,521
Total liabilities and stockholders’ equity	$532,984	$734,733

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.